This site is intended for U.S. healthcare professionals.

Dosing and
Administration

ONUREG® offers convenient, once-daily, oral dosing that patients can take at home1

The recommended dosage of ONUREG® is one 300 mg tablet orally, once daily with or without food on Days 1-14 of each 28-day treatment cycle1

Recommended dosage1

ONUREG® Recommended Dosing ONUREG® Recommended Dosing Patients should take an antiemetic 30 minutes prior to each dose of ONUREG® for the first 2 cycles. Antiemetic prophylaxis may be omitted after 2 cycles if there has been no nausea and vomiting Continue ONUREG® until disease progression or unacceptable toxicity
  • Do not substitute ONUREG® for intravenous or subcutaneous azacitidine. The indications and dosing regimen for ONUREG® differ from that of intravenous or subcutaneous azacitidine
  • If the absolute neutrophil count (ANC) is <0.5 Gi/L on Day 1 of a cycle, do not administer ONUREG®. Delay the start of the cycle until the ANC is ≥0.5 Gi/L

Administration1

Instruct patients on the following1:

Take a dose about the
same time each day

Swallow tablets whole.
Do not cut, crush, or chew tablets*

  • If a dose of ONUREG® is missed, or not taken at the usual time, take the dose as soon as possible on the same day, and resume the normal schedule the following day. Do not take 2 doses on the same day
  • If a dose is vomited, do not take another dose on the same day. Resume the normal schedule the following day

*ONUREG® is a hazardous drug. Follow applicable special handling and disposal procedures. If powder comes in contact with skin, immediately and thoroughly wash with soap and water. If powder comes in contact with mucous membranes, immediately flush the area with water.

Dosage modifications for adverse reactions1

Recommended dosage modifications for ARs1

Monitor complete blood count every other week for the first 2 cycles of each 28-day treatment cycle and prior to the start of the next cycle thereafter. Increase monitoring to every other week for the 2 cycles of each 28-day treatment cycle after any dose reduction for myelosuppression.

Myelosuppression

GI Toxicity or Other ARs

ONUREG® tablets are available in 2 strengths for once-daily, oral dosing1

300 and 200 mg ONUREG® Tablet 300 and 200 mg ONUREG® Tablet

Storage1

Storing ONUREG® blister cards
  • ONUREG® tablets are supplied in a blister card containing 7 tablets. Store at 68°F to 77°F (20°C to 25ºC)
  • Excursions permitted between 59°F to 86°F (15°C to 30°C)
    (see USP Controlled Room Temperature)
  • Store in the original aluminum blisters
ONUREG® Blister Card

Handling and disposal1

ONUREG® is a hazardous drug. Follow applicable special handling and disposal procedures. If powder comes in contact with skin, immediately and thoroughly wash with soap and water. If powder comes in contact with mucous membranes, immediately flush the area with water.

This site is best viewed in portrait mode on a smartphone or small tablet.